Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

538
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
538
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

274
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
274
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

3.4K
The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
3.4K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

630
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
630
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

707
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
707
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

301
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
301

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of stent materials and hemodynamic changes after endovascular aneurysm repair for abdominal aortic aneurysm.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

Change in dapagliflozin trial eligibility status and prognosis among patients with acute heart failure with preserved ejection fraction.

Journal of the Chinese Medical Association : JCMA·2026
Same author

Cardiovascular benefits of early sodium-glucose cotransporter 2 inhibitor use for diabetics with acute myocardial infarction: A nationwide cohort study.

British journal of clinical pharmacology·2025
Same author

Management of HFpEF in Asian Patients: Evidence from Major Trials on HFpEF Therapeutics.

JACC. Asia·2025
Same author

A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.

European journal of heart failure·2025
Same author

Differential Impacts of Resting and Exercise-related Blood Pressure Changes on Cardiovascular and All-cause Mortalities.

American journal of hypertension·2025

Related Experiment Video

Updated: Dec 27, 2025

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.2K

Second revolution in cardiovascular prevention.

Chern-En Chiang1,2,3, Kang-Ling Wang1,2,3, Hao-Min Cheng2,3,4

  • 1General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.

Journal of the Chinese Medical Association : JCMA
|February 27, 2020
PubMed
Summary
This summary is machine-generated.

Sodium-glucose transport protein 2 inhibitors (SGLT-2 i) offer a second revolution in cardiovascular prevention for type 2 diabetes patients. These drugs significantly reduce chronic kidney disease and heart failure, complementing statin therapy.

More Related Videos

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.9K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.9K

Related Experiment Videos

Last Updated: Dec 27, 2025

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.2K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.9K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.9K

Area of Science:

  • Endocrinology
  • Nephrology
  • Cardiology

Background:

  • Type 2 diabetes (T2D) prevalence has quadrupled globally, with atherosclerotic cardiovascular disease (ASCVD) as a major complication.
  • Statins revolutionized ASCVD treatment but failed to prevent chronic kidney disease (CKD) and heart failure (HF).
  • Regulatory mandates require new antidiabetic drugs to undergo cardiovascular and renal safety trials.

Purpose of the Study:

  • To evaluate the cardiovascular and renal benefits of newer antidiabetic drug classes.
  • To identify therapeutic agents that decrease blood glucose and reduce cardiovascular and renal disease.
  • To highlight the role of sodium-glucose transport protein 2 inhibitors (SGLT-2 i) in managing T2D complications.

Main Methods:

  • Review of clinical trial data for glucagon-like peptide-1 receptor agonists and SGLT-2 inhibitors.
  • Analysis of the CREDENCE trial results for canagliflozin's effect on renal endpoints.
  • Examination of the DAPA-HF trial results for dapagliflozin's effect on heart failure and mortality.

Main Results:

  • SGLT-2 inhibitors demonstrate significant efficacy in preventing CKD progression and end-stage renal disease.
  • Canagliflozin reduced renal endpoints by 34% and end-stage renal disease by 32% in the CREDENCE trial.
  • Dapagliflozin decreased HF hospitalizations/cardiovascular death by 26% and total death by 17% in the DAPA-HF trial, irrespective of diabetes status.

Conclusions:

  • SGLT-2 inhibitors offer substantial benefits for CKD and HF, complementing statin therapy.
  • The efficacy of SGLT-2 inhibitors in preventing cardiovascular and renal disease marks a significant advancement.
  • The introduction of SGLT-2 inhibitors represents a second revolution in cardiovascular prevention strategies for T2D.